Kategorie: Genitourinární nádory
Číslo abstraktu: 046
Autoři: Prof.MD Cezary Szczylik, Ph.D.
Renal cell carcinoma is the most frequent occurring solid lesion within the kidney and comprises different RCCC types with specific histopathological and genetic characteristic.
There is a 1.5:1 predominance of men over women. Renal cell carcinoma represents 2-3% of all cancers, with the highest incidence occurring in the more developing countries. The worldwide and European annual increase in incidence is approximately 2%. Every year approximately 30 000 new RCC cases are registered in EU countries and 15 000 died of the disease. RCC detection in recent years is improved due to increased numbers of imaging techniques such as ultrasound and computerized tomography. Despite the increased incidental detection rate, the mortality from RCC remained unaffected and parallel to incidence (EAU report). The leading cause of malignant proliferation in sporadic clear cell RCC is HIF (hypoxia inducible factor) accumulation due to VHL (von Hippel-Lindau) gene inactivation with subsequent overexpression of VEGF and PDGF, both promoting angiogenesis. Recently many active antiangiogenic drugs have been developed and approved both in USA and EU for treatment of metastatic renal cell carcinoma: sorafenib, sunitinib, temsirolimus, everolimus, avastin and pazopanib.
The objectives of presentation are to evaluate the growing body of knowledge regarding clinical and molecular characteristics of novel compounds and data from recent clinical trials. Data from clinical trials will be reviewed to define algorithms of treatment of metastatic renal cell carcinoma.
Datum přednesení příspěvku: 28. 1. 2011